Original Research ARTICLE
Hypomethylation of 111 probes Predicts poor prognosis for Glioblastoma
- 1PLA General Hospital, China
- 2University of Texas MD Anderson Cancer Center, United States
Glioblastoma is a complicated brain tumor with heterogeneous outcome. Identification of effective biomarkers is an urgent need for the treatment decision-making and precise evaluation of prognosis. Based on a relatively large dataset of genome-wide methylation (138 patients), a joint-score of 111 methyl-probes was found to be of statistical significance for prognostic evaluation. Low joint-score were significantly associated with adverse outcomes (OS: P < 0.001). Multivariable analyses adjusted for known risk factors confirmed the low joint-score of 111 methyl-probes as a high risk factor. The prognostic value of joint-score was further validated in another dataset of glioblastoma patients (OS: P = 0.006). Additionally, variance analysis revealed that aberrant genetic and epigenetic alterations were significantly associated with the joint-score of those methyl-probes. In conclusion, our results supported the joint-score of 111 methyl-probes as a potential prognosticator for the precision treatment of glioblastoma.
Keywords: Glioblastoma, biomarker, Methylation, Prognostic evaluation, joint-score
Received: 03 Dec 2018;
Accepted: 09 Oct 2019.
Copyright: © 2019 Shi, Chen, Zhao, Yin, Feng, Hu, Zhang, Ma and Xue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Jinlong Shi, PLA General Hospital, Beijing, China, firstname.lastname@example.org